Clinical Trial Update: A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BCD-022 with paclitaxel to Herceptin with paclitaxel in HER2-positive metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BCD-022 with paclitaxel (BCD-022)
• Herceptin with paclitaxel (trastuzumab)

Snippet

Sponsor: Biocad | Conditions: Human Epithelial Receptor (HER)-2 Positive Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-10-24